Residency · Kansas City, KS
Sponsored by University of Kansas School of Medicine
Trial of Endovascular Thrombectomy for Large Ischemic Strokes.
The New England journal of medicine · 2023 · 798 citations · Michael Abraham, Laith Maali, Faris Shaker
The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis.
Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023 · 395 citations · Russell Swerdlow
Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline.
Neurology · 2023 · 167 citations · Gary Gronseth
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
The Lancet. Oncology · 2021 · 600 citations · Natalie Byrne
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
Nature medicine · 2025 · 98 citations · Jeffrey Burns
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
The Lancet. Neurology · 2025 · 76 citations · Constantine Farmakidis
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
The Lancet. Neurology · 2024 · 126 citations · Rajesh Pahwa
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Frontiers in neurology · 2023 · 78 citations · Mamatha Pasnoor